Why Relay Therapeutics Is Up 30% This Week

Why Relay Therapeutics Is Up 30% This Week
·2 min read

What happened Shares of Relay Therapeutics (NASDAQ: RLAY), a clinical-stage biopharmaceutical company, have risen about 30% since the stock's closing price last Friday. Investors are highly encouraged by interim clinical trial data that suggest the company's new approach to drug development can produce a new blockbuster cancer treatment.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting